Wilmington, Delaware-based Incyte Corporation (INCY) is a biopharmaceutical company that engages in the discovery, development, and commercialization of therapeutics in the United States and internationally. The company has a market cap of $19.6 billion and offers JAKAFI for the treatment of myelofibrosis, ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia, and other products.
Companies with a market cap of $10 billion or more are typically referred to as “big-cap stocks.” INCY fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the biotechnology industry.